NHS National Framework Agreement for Macitentan & Cladribine Tablets
The contract covers a national NHS framework for the supply of macitentan and cladribine tablets, procured by NHS England through Medicines Procurement and Supply Chain – NHS Medicines Value & Access, the function responsible for medicines procurement and supply across the UK health service. Suppliers will be expected to provide the specified medicines under separate regional lots, supporting NHS demand and complying with the framework’s product and supply requirements. Macitentan is divided into three lots, with initial terms of 24 months except for the DNW/DLS lot, which runs for 16 months; cladribine tablets comprise three lots with initial terms of 24, 16 and 12 months respectively, beginning from October 2027. The estimated total value is £128.4 million, with extensions available at the Authority’s discretion for up to a maximum of 24 months. Delivery covers NHS regions across England, including the North East, North West, Yorkshire and the Humber, East and West Midlands, East of England, London, South East and South West. The critical qualification is the ability to supply the specified medicinal products in accordance with NHS pharmaceutical procurement and supply requirements.
Buyer: NHS England. Source: Find a Tender. Updated 3 Nov 2026.
Key facts
- Estimated value: £128.4m
- Bids close: Not open for bids yet
- Location: North East (England), North West (England), East Midlands (England), West Midlands (England), East of England, South East (England), South West (England), Lambeth
- Contract period: 1 Oct 2027 to 30 Sept 2029
- Category: Pharmaceutical products (33600000)
From the official notice
Project title: NHS National Framework Agreement for Macitentan & Cladribine Tablets Offer reference number: CM/TNS/26/5748 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5748/01 Macitentan Lot 1 DCE/DLN: 01/10/2027 to 30/09/2029 (24 months) CELN Lot 2 DNW/DLS: 01/10/2027 to 31/01/2029 (16 months) NWLS Lot 3 DNE/DSW: 01/10/2027 to 30/09/2029 (24 months) NESW CM/TNS/26/5748/02 Cladribine Tablets Lot 1 DCE/DSW: 01/10/2027 to 30/09/2029 (24 months) CESW Lot 2 DLN/DNW: 01/10/2027 to 31/01/2029 (16 months) NWLN Lot 3 DLS/DNE: 01/10/2027 to 30/09/2028 (12 months) LSNE Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Questions about this tender
When is the deadline?
Bidding has not opened yet. The buyer has published it as a planned tender.
What is it worth?
The estimated value is £128.4m.
Who can apply?
The buyer has marked it as suitable for small and medium-sized businesses.
How do I bid?
You cannot bid yet. Follow the official notice for the competition that comes next, and check how the buyer's portal lets suppliers register.
- More Medical equipments, pharmaceuticals and personal care products tenders
- More tenders in North East
- More tenders from NHS England
Similar tenders
- Medicinal Products Dynamic Purchasing System [131864]
- Personal Protective Equipment 2884208
- CPH131 Prescribing only Medication (POM) and Nicotine Replacement Therapy (NRT)
Contains public sector information licensed under the Open Government Licence v3.0.